|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Karyopharm Therapeutics insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Karyopharm Therapeutics insider buys are important for investors to follow.
Date | Insider | Price | Amount |
9-12-2023 Insider Buy |
Garen G. Bohlin
|
$1.22
CAGR »
|
$49,985.10 41,140 shares |
5-7-2021 Insider Buy |
Jatin Shah EVP, Chief Medical Officer |
$8.60
CAGR »
|
$199,991.85 23,250 shares |
5-6-2021 Insider Buy |
Garen G. Bohlin Director |
$7.82
CAGR »
|
$31,280.00 4,000 shares |
8-26-2020 Insider Buy |
John Demaree Chief Commercial Officer |
$14.54
CAGR »
|
$109,012.50 7,500 shares |
4-7-2015 Insider Buy |
Ran Frenkel EVP, WW Development Operations |
$31.81
CAGR »
|
$95,430.00 3,000 shares |
4-2-2015 Insider Buy |
Justin A. Renz EVP, CFO & Treasurer |
$29.71
CAGR »
|
$148,557.00 5,000 shares |
4-2-2015 Insider Buy |
Barry E. Greene Director |
$29.31
CAGR »
|
$87,938.40 3,000 shares |
1-12-2015 Insider Buy |
Deepika Pakianathan Director |
$33.00
CAGR »
|
$1,499,982.00 45,454 shares |
5-23-2014 Insider Buy |
Deepika Pakianathan Director |
$26.18
CAGR »
|
$2,995,462.14 114,419 shares |
5-15-2014 Insider Buy |
Paul Brannelly SVP, FINANCE & ADMIN, TREAS |
$25.95
CAGR »
|
$18,165.00 700 shares |
5-14-2014 Insider Buy |
Paul Brannelly SVP, FINANCE & ADMIN, TREAS |
$26.93
CAGR »
|
$21,544.00 800 shares |
5-13-2014 Insider Buy |
Paul Brannelly SVP, FINANCE & ADMIN, TREAS |
$28.06
CAGR »
|
$28,057.40 1,000 shares |
5-13-2014 Insider Buy |
Christopher Brett Primiano VP, GEN COUNSEL & SECRETARY |
$26.75
CAGR »
|
$26,750.00 1,000 shares |
11-12-2013 Insider Buy |
Deepika Pakianathan Director |
$16.00
CAGR »
|
$5,000,000.00 312,500 shares |
Also See: Institutional Holders of KPTI
Also See: SEC filings
Below we present the annualized performance delivered by Karyopharm Therapeutics stock since 9-12-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Karyopharm Therapeutics insider buying occurred is the ultimate
test of whether insiders were right about KPTI being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/13/2023 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$1.28 |
|
End price/share: |
$1.06 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-17.19% |
|
Annualized Gain: |
-27.76% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$8,281.00 |
|
Years: |
0.62 |
|
Karyopharm Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Karyopharm Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding KPTI
|
|